曲妥珠单抗在HER2阳性乳腺癌脑转移患者中的作用。 - Suppr | 超能文献

Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.

作者信息

Bulut Nilufer, Harputluoglu Hakan, Dizdar Omer, Altundag Kadri

出版信息

J Neurooncol. 2008 Jan;86(2):241. doi: 10.1007/s11060-007-9447-7. Epub 2007 Jul 6.

DOI:10.1007/s11060-007-9447-7

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer.曲妥珠单抗在HER2阳性乳腺癌脑转移患者中的作用。

J Neurooncol. 2008 Jan;86(2):241. doi: 10.1007/s11060-007-9447-7. Epub 2007 Jul 6.

2

Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.在伴有脑转移和血脑屏障受损的HER2阳性乳腺癌患者中，血清和脑脊液中曲妥珠单抗水平的比率发生了改变。

Anticancer Drugs. 2007 Jan;18(1):23-8. doi: 10.1097/01.cad.0000236313.50833.ee.

3

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.HER2 阳性乳腺癌脑转移的全身治疗：现状与未来方向。

Future Oncol. 2012 Feb;8(2):135-44. doi: 10.2217/fon.11.149.

4

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.曲妥珠单抗可延长Her2阳性乳腺癌脑转移患者的总生存期。

J Neurooncol. 2007 Dec;85(3):311-7. doi: 10.1007/s11060-007-9420-5. Epub 2007 Jun 8.

5

Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.曲妥珠单抗增敏化疗耐药、局部晚期或局部复发性乳腺癌的疗效：一项 II 期试验。

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):998-1004. doi: 10.1016/j.ijrobp.2009.03.027. Epub 2009 Jun 27.

6

[Brain metastases in breast cancer: a special disease course for HER2 positive tumors].[乳腺癌脑转移：HER2阳性肿瘤的特殊病程]

Ned Tijdschr Geneeskd. 2008 Dec 13;152(50):2701-6.

7

Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.对于先前接受基于曲妥珠单抗治疗转移性乳腺癌的脑转移患者使用曲妥珠单抗的理论依据。

Breast. 2005 Oct;14(5):425. doi: 10.1016/j.breast.2004.08.016.

8

Trastuzumab treatment beyond brain progression in HER2- positive metastatic breast cancer.曲妥珠单抗用于HER2阳性转移性乳腺癌脑转移进展后的治疗。

Ann Oncol. 2009 Jan;20(1):192. doi: 10.1093/annonc/mdn631.

9

[Trastuzumab and blood-brain barrier].[曲妥珠单抗与血脑屏障]

Bull Cancer. 2007 Oct;94(10):857-9.

10

Treatment of brain metastases in patients with HER2+ breast cancer.曲妥珠单抗联合全脑放疗治疗 HER2+乳腺癌脑转移患者的疗效和安全性

Adv Ther. 2009 Jul;26 Suppl 1:S18-26. doi: 10.1007/s12325-009-0047-0. Epub 2009 Jul 24.

本文引用的文献

1

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.曲妥珠单抗可延长Her2阳性乳腺癌脑转移患者的总生存期。

J Neurooncol. 2007 Dec;85(3):311-7. doi: 10.1007/s11060-007-9420-5. Epub 2007 Jun 8.

2

Sensitization of breast cancer cells to radiation by trastuzumab.曲妥珠单抗使乳腺癌细胞对放疗敏感。

Mol Cancer Ther. 2003 Nov;2(11):1113-20.

3

Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).放疗引起的血脑屏障通透性变化：对化疗时机的影响？（综述）

Oncol Rep. 2002 Jul-Aug;9(4):683-8.